Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2015
At a glance
- Drugs Lenalidomide (Primary)
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Adverse reactions
- Acronyms REVALLO
- 31 Jul 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 29 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Aug 2011 New trial record